MLQ.ai | Stocks

Genetron Holdings (GTH) News

Price: $4.025
Market Cap: $127.29M
Avg Volume: 51.86K

Country: CN
Industry: Medical - Diagnostics & Research
Sector: Healthcare

Beta: 0.50
52W Range: $2.0802-4.05
Website: Genetron Holdings

Related Tools

🗞️ Stock News Assistant

Get concise summaries, analyze trends, and ask questions about stock-related news.

Use Tool

✍️ AI Journalist

Input a topic and GPT will search the web, find relevants articles, and write an article based on the research.

Use Tool

Gathid Sets New Identity and Access Governance Standard with Introduction of Patented Identity Model

Patented directed graph model delivers immediate, low-risk visibility of your identities and access in days, not months GOLD COAST, Australia & SEATTLE–(BUSINESS WIRE)–Gathid (ASX: GTH) today announced the debut of its new approach to identity and access governance. Inspired by the power of gathered identities, the platform pinpoints identity and access anomalies with its patented … The post Gathid Sets New Identity and Access Governance Standard with Introduction of Patented Identity Model appe...

headlinesoftoday.com

Genetron Health Announces Completion of Going Private

BEIJING, March 28, 2024 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger … The post Genetron Health Announces Completion of Going Private appeared first on Headlines of Toda...

headlinesoftoday.com

Genetron Health Announces Completion of Going Private Transaction

BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger Sub”), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and will cease to be a publicly traded company.

globenewswire.com

Genetron Health Announces Shareholders' Approval of Merger Agreement

BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the “EGM”) held today, the Company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), pursuant to which, Merger Sub will be merged with and into the Company with the Company continuing as the surviving company and becoming a wholly owned subsidiary of Parent (the “Merger”), the plan of merger (the “Plan of Merger”) required to be filed with the Registrar of Companies of the Cayman Islands, and the transactions contemplated thereby, including the Merger.

globenewswire.com

Genetron Health to Hold Extraordinary General Meeting of Shareholders

BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changping District, Beijing, People's Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the “Plan of Merger”) and the transactions contemplated thereby, including the Merger (as defined below).

globenewswire.com

Genetron stock rallies on CEO-led deal to go private

Genetron Holdings has announced it will go private through an acquisition by a group of investors led by its co-founder and CEO Sizhen Wang and CICC Healthcare Investment Fund which values the Chinese precision oncology platform at US$126 million. The company's US-listed American Depository Shares (ADSs) jumped 27% in early Thursday trading to $1.1950.

proactiveinvestors.com

Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction

BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement and subject to the terms and conditions thereof, Merger Sub will merge with and into the Company, with the Company continuing as the surviving entity and becoming a wholly-owned subsidiary of Parent (the “Merger”), in a transaction implying an equity value of the Company of approximately US$126.0 million.

globenewswire.com

Genetron Health Announces Receipt of Notification from

BEIJING, May 23, 2023 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications […]...

headlinesoftoday.com

Genetron Health Announces Receipt of a Preliminary

BEIJING, Aug. 22, 2022 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that its Board of Directors (the “Board”) has received a preliminary non-binding proposal […]...

headlinesoftoday.com

Genetron Holdings Limited (GTH) CEO Sizhen Wang on Q1 2022 Results - Earnings Call Transcript

Genetron Holdings Limited (NASDAQ:GTH ) Q1 2022 Earnings Conference Call June 2, 2022 8:30 AM ET Company Participants Evan Xu - Chief Financial Officer Sizhen Wang - Co-Founder, Chairman & Chief Executive Officer Conference Call Participants Yang Huang - Credit Suisse Operator Good morning, and thank you for standing by. Welcome to the First Quarter 2022 Genetron Health Earnings Conference Call.

seekingalpha.com

Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022

BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open.

globenewswire.com

Genetron Holdings Limited's (GTH) CEO Sizhen Wang on Q4 2021 Results - Earnings Call Transcript

seekingalpha.com

Arima Genomics Closes Series B Financing to Support Growing Portfolio of 3D Genomics Solutions for Biomedical Research and Translational Applications

SAN DIEGO--(BUSINESS WIRE)-- #3Dgenomics--Arima Genomics closes $7M series B financing to support continued growth of 3D genomics portfolio for research and translational applications.

businesswire.com

Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on March 29, 2022

BEIJING, March 09, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the fourth quarter and full year ended December 31, 2021 on March 29, 2022 before the US market open.

globenewswire.com

Genetron Health to Participate in Upcoming Investor Conferences

BEIJING, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will be participating in two upcoming virtual investor conferences.

globenewswire.com

Genetron Holdings Limited (GTH) CEO Sizhen Wang On Q3 2021 Results - Earnings Call Transcript

seekingalpha.com

Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline

BEIJING, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a partnership with IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics.

globenewswire.com

Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021

BEIJING, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has partnered with a consortium of 14 top Chinese hospitals to release 13 key research findings at the ESMO 2021 Congress, hosted by the European Society for Medical Oncology. The findings focus on the exploration of genomics amongst the Chinese population, and provide important insights for clinical pathology classification, targeted therapy and immunotherapy strategies, and the clinical management of hereditary colorectal cancer.

globenewswire.com

Genetron Added to FTSE Russell Global Equity Index Series

BEIJING, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), today announced that Genetron will be added to the below FTSE Global Equity Index Series ("GEIS"), following FTSE's most recent quarterly review. These inclusions will become effective after the market close on Friday, September 17, 2021:

globenewswire.com

Genetron Health's Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021

BEIJING, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Co-Founder and Chief Scientific Officer, Dr. Hai Yan, was awarded the International Prize for Translational Neuroscience 2021. Awarded by the Gertrud Reemtsma Foundation through the Max Planck Society, the prize is one of the most prominent awards in neuroscience and recognizes individuals who have made outstanding and original contributions to the understanding of neurobiology and neurological disease. The ceremony took place at the Max-Planck-Institute in Cologne, Germany, on August 26.

globenewswire.com

Genetron Holdings Limited (GTH) CEO Sizhen Wang on Q2 2021 Results - Earnings Call Transcript

seekingalpha.com

Genetron Holdings: Q2 Earnings Insights

Shares of Genetron Holdings (NASDAQ:GTH) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 31.58% year over year to ($0.13), which beat the estimate of ($0.91).

benzinga.com

Genetron Health Reports Second Quarter 2021 Unaudited Financial Results

BEIJING, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the second quarter ended June 30, 2021.

globenewswire.com

Genetron Health to Host Calls Following Earnings and Participate in an Upcoming Investor Conference

BEIJING, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will host calls with various brokers following second quarter earnings and participate in an investor conference with Wells Fargo.

globenewswire.com

Genetron Health Tops NCCL's External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks

BEIJING, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Beijing clinical laboratory has received full marks under the National Center for Clinical Laboratories' (“NCCL”) first nationwide, external quality assessment (“EQA”) of NGS-based comprehensive genomic profiling for solid tumors. The clinical laboratory passed the assessment with flying colors, earning the designation “Outstanding Laboratory” and receiving full marks, ranking first among all of the 63 laboratories that participated in the evaluation.

globenewswire.com

Genetron Health Partners with Guizhou Province's Dafang County to Lead Liver Cancer Early Screening Project

BEIJING, July 29, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will work with Guizhou Province's Dafang County authorities to lead the “Early Screening for Regional Liver Cancer Prevention and Containment Demonstration Project”. Backed by the Central Committee of the Chinese Peasants and Workers Democratic Party and guided by China's National Cancer Center, this project is a collective effort that will be carried out by the Dafang County Health Bureau, the People's Hospital of Dafang, and Genetron Health.

globenewswire.com

AYVAKIT® (avapritinib) Companion Diagnostic Test Enters Priority Review and Approval Process in China

BEIJING, July 26, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), today announced that its AYVAKIT® (avapritinib) companion diagnostic (CDx) kit, developed in partnership with CStone Pharmaceuticals (“CStone”, HKEX: 2616) has entered the priority review and approval process under the National Medical Products Administration (NMPA) in China.

globenewswire.com

Genetron Health Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test

The CE Mark and comparative data highlight the Company's capability in providing high quality and consistent testing products The CE Mark and comparative data highlight the Company's capability in providing high quality and consistent testing products

globenewswire.com

Genetron Health Enters into Platform Partnership with World Economic Forum

BEIJING, July 02, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced a new partnership with the World Economic Forum (WEF), under its Health and Healthcare Platform.

globenewswire.com

Genetron Health Releases 16 New Research Results at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

BEIJING, June 04, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 16 research results at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

globenewswire.com

Genetron Holdings: Solid Revenue Growth Continues While Earnings Move Toward Profitability

Genetron Holdings announced earnings results on May 24 and the company saw strong revenue growth for the first quarter.

seekingalpha.com

Genetron Holdings Limited (GTH) CEO Sizhen Wang on Q1 2021 Results - Earnings Call Transcript

seekingalpha.com

Genetron Health Reports First Quarter 2021 Unaudited Financial Results

BEIJING, May 24, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the first quarter ended March 31, 2021.

globenewswire.com

Genetron Holdings (GTH) Stock: Over 10% Increase Explanation

The stock price of Genetron Holdings Ltd (NASDAQ: GTH) increased by over 10% during intraday trading. This is why it happened.

pulse2.com

Genetron Health Announces Strategic Partnership with JD Health to Create Innovative Solutions for Full-cycle Cancer Management

BEIJING, May 20, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a strategic partnership with JD Health, a subsidiary of JD.com, Inc., and the largest online healthcare platform in China. The two companies aim to create innovative solutions for full-cycle cancer management.

globenewswire.com

3 Small Cap Stocks That Are Short Squeeze Candidates

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

benzinga.com

Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer

SHANGHAI--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a strategic partnership with Siemens Healthineers at the China Medical Equipment Fair. This partnership aims to promote large scale application of Genetron's S5 platform and lung cancer 8-gene IVD a

businesswire.com

Genetron Health to Announce First Quarter 2021 Financial Results and Host Investor Call on May 24, 2021

BEIJING, May 03, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2021 on May 24, 2021 before the US market open.

globenewswire.com

Genetron Health to Present at Upcoming Investor Conferences

BEIJING, April 22, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present and host one-on-one meetings at three upcoming investor conferences.

globenewswire.com

Genetron Health Releases 22 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2021

businesswire.com

Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit

BEIJING, April 01, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit on Wednesday April 7th, 2021.

globenewswire.com

Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science/AAAS Webinar

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH) sponsored a Science/AAAS Webinar, “Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment”, which launched today. During the panel discussion, Genetron Health's Chief Technology Officer, Dr. Yuchen Jiao, gave a speech entitled “Profiling cfDNA-based Biomarkers for the Early Detection of Cancer”. In his presentation, Dr. Jiao highlighted the impo

businesswire.com

Genetron Health Reports Unaudited Fourth Quarter and Full Year 2020 Financial Results, and Provides 2021 Revenue Guidance

businesswire.com

Genetron Health Releases New Data Results of HCCscreen™ for Liver Cancer Early Screening in China

businesswire.com

Genetron Health to Present at Science/AAAS Webinar About Early Cancer Screening on March 31

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the company will present at one of the Science/AAAS Webinar Series, “Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment”. The webinar will be available o

businesswire.com

Genetron Health to Announce Fourth Quarter and Full Year 2020 Unaudited Financial Results and Host Investor Call on March 25, 2021

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the fourth quarter and full year ended December 31, 2020 on March 25, 2021 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, March 25, 2021. The conference call can be accessed by dialing the following numbers: United States: +1-845-675-0437 China Domestic: 400-620-8038 Hong Kong: +852-3018-6771 International: +65-6713-5090 Conference ID: 5379298 Participants are encouraged to dial into the call at least 15 minutes in advance due to high call volumes. A replay will be accessible through April 2, 2021 by dialing the following numbers: Telco replay number United States: +1-855-452-5696 International: +61-2-8199-0299 Conference ID: 5379298 A simultaneous webcast of the conference call will be available on the "News and Events" page of the Investors section of the Company's website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.genetronhealth.com. About Genetron Holdings Limited Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com. Safe Harbor Statement This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

businesswire.com

Genetron Health's Early Liver Cancer Screening Research Results Included in First Prevention and Treatment Guidelines for Patients in China

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its early liver cancer screening research results were cited by the "Chinese Anti-Cancer Association Guidelines for Patients with Primary Liver Cancer" (the "Guidelines"). The Guidelines, issued by the

businesswire.com

Genetron Health to Release Thirteen Research Findings at 21st World Conference on Lung Cancer

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will release thirteen new research findings at the 21st World Conference on Lung Cancer (WCLC), which will be held virtually from January 28 to 31. One of the research findings (Study 3713) was sele

businesswire.com

Genetron Health to Present at BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021. Yunfu Hu, PhD, Chief Medical Officer of Genetron Health, is sch

businesswire.com

Genetron Health Announces Exclusive Strategic Partnership with Sino Biopharm Subsidiary for HCCscreen™ in China

NANJING, China--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), a subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX: 1177), today announced an exclusive strategic partnership agreement for HCCscree

businesswire.com

Week In Review: Eluminex Raises $50 Million For Ophthalmology Drugs

Genetron Health, a Beijing-North Caroline diagnostic company, announced a city-wide early screening test for liver cancer in Wuxi city using the company's blood-based HCCscreen. Sinopharm has filed for China approval of at least one of its two COVID-19 inactivated vaccines based on initial data from a global Phase III trial, according to a Bloomberg report.

seekingalpha.com

COVID-19 Highlights Role of Early Detection in Fighting Threatening Diseases, Especially Cancer, Genetron CEO Tells CNBC Conference

BEIJING--(BUSINESS WIRE)--The global COVID-19 pandemic has highlighted the critical importance of early detection and intervention in fighting other life-threatening diseases, such as cancer, according to Sizhen Wang, co-founder and chief executive officer of Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH). “Wide-scale testing plays a crucial role in China's successful control of COVID-19. Besides the pandemic this year, there are many other life-threatening diseases

businesswire.com

Genetron Holdings Reports Continued Positive Revenue Trajectory

Genetron Holdings went public in June 2020 and just reported its Q3 2020 results. The firm provides a range of cancer diagnostic and monitoring services in China.

seekingalpha.com

Genetron Health Reports Third Quarter 2020 Unaudited Financial Results and Provides Business Update

BEIJING, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited financial results for the third quarter ended September 30, 2020 and provided an update on recent developments.

globenewswire.com

Genetron Health to Present at Six Upcoming Investor and Industry Conferences

BEIJING, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present and host 1x1 investor meetings at six upcoming investor and industry conferences.

globenewswire.com

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc...

benzinga.com

Global Genetic Testing Market Size Forecast to 2023 - ResearchAndMarkets.com

The

businesswire.com

Next Generation Cancer Diagnostics: Technologies and Global Markets (2019-2025) - ResearchAndMarkets.com

The

businesswire.com

U.S. IPO Week Ahead: GoHealth Takes The Lead In A 4-IPO Week

Four IPOs and one SPAC plan to raise $1.5 billion in the week ahead, led by health insurance marketplace GoHealth.

seekingalpha.com

U.S. IPO Weekly Recap: Royalty Pharma Takes The Crown In 5 IPO Week

Five IPOs and one SPAC went public this past week led by Royalty Pharma. Healthcare continued to dominate, with all five IPOs coming from the sector. Seven IPOs

seekingalpha.com

IPO Update: Genetron Holdings Files Proposed IPO Terms (Pending:GTH)

Genetron Holdings aims to raise $162.5 million in a U.S. IPO. The firm provides a range of cancer diagnostics and related services in China. GTH has suffered te

seekingalpha.com